Purchase of GMP grade crispr base-editing guide RNA for xscid patients at the clinical center. Synthego holdings LLC (ambis #2280586)
Active Purchase Order Awarded Last action
- Contract number
- 75N98026P00112
- Awardee
-
Synthego Holdings LLC UEI QAEMBLSJP2B5
- Awarding agency
-
Office of Logisitics and Acquisition Operations
National Institutes of Health, Department of Health and Human Services
- Obligated
- $140,000
Award facts
- Contract value 100% obligated
- $140,000.00 Current and potential, with all options
- Completion date 61% complete
- Current and potential, with all options
- Funding agency
- National Institute of Allergy and Infectious Diseases National Institutes of Health, Department of Health and Human Services
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- 1 offer Only One Source
- Pricing
- Firm Fixed Price
- Place of performance
- North Bethesda, MD 20852, USA
Award details come from SAM.gov/FPDS.
About this award
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $140,000 firm fixed-price purchase order to Synthego Holdings LLC for the procurement of GMP-grade CRISPR base-editing guide RNA intended for X-linked severe combined immunodeficiency (XSCID) patients at the NIH Clinical Center. The contract, awarded on March 11, 2026, with an ultimate completion date of March 10, 2027, represents a targeted procurement of specialized genetic engineering materials to support advanced therapeutic research and potential clinical applications. No set-aside designation was applied to this award.
The work will be performed in Rockville, Maryland, leveraging Synthego's expertise in manufacturing clinical-grade synthetic RNA molecules. XSCID is a severe genetic disorder affecting immune system development, and this procurement supports NIAID's mission to develop innovative treatments for immunological diseases. The GMP-grade specification indicates the guide RNA must meet pharmaceutical manufacturing standards suitable for human clinical use, reflecting the advanced nature of this gene-editing research initiative within the federal clinical research enterprise.
Quick answers
Who was awarded contract 75N98026P00112?
75N98026P00112 was awarded to Synthego Holdings LLC by Office of Logisitics and Acquisition Operations (National Institutes of Health) on March 11, 2026.
How much is contract 75N98026P00112 worth?
The government has obligated $140,000 on 75N98026P00112.
Which agency awarded contract 75N98026P00112?
Office of Logisitics and Acquisition Operations (National Institutes of Health) awarded 75N98026P00112, with funding from National Institute of Allergy and Infectious Diseases (National Institutes of Health).
Was contract 75N98026P00112 competed?
The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award